Heather Baumhauer, MERIT's VP of Clinical Services, discusses project management's role at MERIT and describes her journey into the world of clinical research....
Author: clients_p17yrv
Julia Oxley, MERIT's Director of Business Development, discusses her team’s role at MERIT and her passion for clinical research....
Article, Clinical Endpoint Experts / 09.08.2023
4 Reasons to Partner with a Respiratory Clinical Endpoint Expert
Discover 4 reasons to partner with a clinical endpoint expert for your next respiratory trial....
Learn five facts about the current state of clinical trials including details about trial costs, enrollment issues, and the difficulty and complexity of today's studies....
Article, Oncology / 21.06.2023
Treating Lung Cancer with Antibody-Drug Conjugates: Advancing Clinical Trials and New Updates at ASCO 2023
Given that the relative survival rate of patients diagnosed with metastatic lung cancer is low, and that traditional chemotherapy and surgery are of limited efficacy, ADCs represent a potentially important treatment option....
Article / 01.06.2023
Validating Your Imaging Data to Secure Funding: Collect and Hold MERIT Webinar Takeaways
MERIT’s most recent webinar provided an interactive Q & A style session discussing how early phase centralized image storage can help sponsors secure funding. ...
Our ophthalmology case studies illustrate how we seamlessly manage the imaging components of your trial, creating efficiencies for your drug development. ...
This article provides a brief overview of Geographic Atrophy (GA) treatments under development....
MERIT’s respiratory case studies demonstrate that our quality overreads, fast turnaround times, and easy-to-reach RTs will help you move your trial forward....
You need a partner that not only delivers access to a deep bench of SMEs and a secure imaging platform, but also has the clinical operations experience to drive study milestone achievement....
Article, Ophthalmology / 28.02.2023
First Anti-VEGF Treatment Approved for Retinopathy of Prematurity
ROP is one of the leading causes of childhood blindness globally. The availability of an FDA approved medication for ROP represents an important alternative for preterm infants and their parents...
Article, Oncology / 13.02.2023
PCWG3 and Oncology Endpoints Webinar Summary PCWG3 and PSMA PET/CT Response Criteria
Learn more about the fundamentals of PCWG3 response criteria, PSMA PET/CT response criteria, data collection, and response assessment....